Please assess the completion status of the following clinical trial:

Trial Title: A Study Of The Safety, Tolerability And Effective Of Voriconazole For The Treatment Of Serious Candida Infection And Candida Infection Of The Throat In Pediatric Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female 2 to \<18 years of age; Subjects 2 to \<12 years of age will be permitted to enroll in this study only after a Pfizer sponsored pharmacokinetic study confirms the proposed dosage corresponding to this age group is appropriate.~* Patients with confirmed Candida infection of the blood, body tissues, or the esophagus.~* Patient's doctor feels voriconazole is an appropriate choice of therapy.~Exclusion Criteria:~* A known allergy to voriconazole or to azole to antifungal drugs.~* Females who are pregnant, lactating (breast feeding) or planning a pregnancy during the course of the study, or who are of childbearing potential and not using highly effective method of birth control.~* A patient who is receiving treatment with a drug know to interfere with the heart's electrical system (QTc prolongation).~* A patient who is receiving treatment with a drug that is not permitted to be used with voriconazole.~* For primary therapy: a patient who has received more than 48 hours of antifungal therapy for the current episode of Candida infection.~* A patient with significant underlying liver disease at the time of enrollment in the study.~* A patient with significant renal disease (CrCl \< 50 ml/min) at the time of enrollment in the study.~* A patient with a high likelihood of death within 72 hours of study enrollment due to factors unrelated to Candida infection.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Active voriconazole (Type: EXPERIMENTAL): All subjects in this study will receive active voriconazole in an open-label fashion; there is no comparator in this study.

Based on this trial design, predict the completion outcome and termination type (if applicable).